Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBT Margin: 2022-2025

Historic EBT Margin for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -154.17%.

  • InMed Pharmaceuticals' EBT Margin fell 2150.00% to -154.17% in Q3 2025 from the same period last year, while for Sep 2025 it was -171.13%, marking a year-over-year decrease of 3386.00%. This contributed to the annual value of -165.14% for FY2025, which is 165.00% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its EBT Margin stood at -154.17% for Q3 2025, which was down 12.48% from -137.07% recorded in Q2 2025.
  • InMed Pharmaceuticals' EBT Margin's 5-year high stood at -14.56% during Q2 2023, with a 5-year trough of -1,528.88% in Q2 2022.
  • Moreover, its 3-year median value for EBT Margin was -150.47% (2024), whereas its average is -157.20%.
  • Its EBT Margin has fluctuated over the past 5 years, first spiked by 151,431bps in 2023, then plummeted by 13,590bps in 2024.
  • Quarterly analysis of 4 years shows InMed Pharmaceuticals' EBT Margin stood at -446.61% in 2022, then soared by 32,742bps to -119.19% in 2023, then crashed by 11,244bps to -231.63% in 2024, then plummeted by 2,150bps to -154.17% in 2025.
  • Its EBT Margin was -154.17% in Q3 2025, compared to -137.07% in Q2 2025 and -168.12% in Q1 2025.